Status:

COMPLETED

Additional MDMA-assisted Therapy for People Who Relapsed After MDMA-assisted Therapy Trial

Lead Sponsor:

Lykos Therapeutics

Conditions:

Posttraumatic Stress Disorder

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

This study will consist of a single session of MDMA-assisted therapy with a full dose of MDMA for people who took part in a study of MDMA-assisted therapy in people with posttraumatic stress disorder ...

Detailed Description

This study will investigate the effects of an additional 3,4-methylenedioxymethamine (MDMA)-assisted therapy session in up to three participants with PTSD who relapsed after their PTSD symptoms had si...

Eligibility Criteria

Inclusion

  • Be diagnosed with chronic PTSD;
  • Have a CAPS score showing moderate to severe PTSD symptoms;
  • Have participated in MP-1;
  • Are at least 18 years old;
  • Must be generally healthy;
  • Must sign a medical release for the investigators to communicate directly with their therapist and doctors;
  • Are willing to refrain from taking any psychiatric medications during the study period;
  • Willing to follow restrictions and guidelines concerning consumption of food, beverages, and nicotine the night before and just prior to each experimental session;
  • Willing to remain overnight at the study site;
  • Agree to have transportation other than driving themselves home or to where they are staying after the integrative session on the day after the MDMA session;
  • Are willing to be contacted via telephone for all necessary telephone contacts;
  • Must have a negative pregnancy test if able to bear children, and agree to use an effective form of birth control;
  • must provide a contact in the event of a participant becoming suicidal;
  • Are proficient in speaking and reading English;
  • agree to have all clinic visit sessions recorded to audio and video
  • Agree not to participate in any other interventional clinical trials during the duration of this study.

Exclusion

  • Are pregnant or nursing, or if a woman who can have children, those who are not practicing an effective means of birth control;
  • Weigh less than 48 kg;
  • Are abusing illegal drugs;
  • Are unable to give adequate informed consent;
  • Upon review of past and current drugs/medication must not be on or have taken a medication that is exclusionary;
  • Upon review of medical or psychiatric history must not have any current or past diagnosis that would be considered a risk to participation in the study.

Key Trial Info

Start Date :

December 15 2010

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 27 2014

Estimated Enrollment :

3 Patients enrolled

Trial Details

Trial ID

NCT01458327

Start Date

December 15 2010

End Date

June 27 2014

Last Update

January 24 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Offices of Michael Mithoefer

Mt. Pleasant, South Carolina, United States, 29464